Literature DB >> 33270553

United States Life Tables, 2018.

Elizabeth Arias, Jiaquan Xu.   

Abstract

Objectives-This report presents complete period life tables for the United States by Hispanic origin, race, and sex, based on age-specific death rates in 2018. Methods-Data used to prepare the 2018 life tables are 2018 final mortality statistics; July 1, 2018 population estimates based on the 2010 decennial census; and 2018 Medicare data for persons aged 66-99. The methodology used to estimate the life tables for the Hispanic population remains unchanged from that developed for the publication of life tables by Hispanic origin for data year 2006. The methodology used to estimate the 2018 life tables for all other groups was first implemented with data year 2008. In 2018, all 50 states and the District of Columbia reported deaths by race based on the 1997 Office of Management and Budget revised standards for the classification of federal data on race and ethnicity. As a result, race-specific life tables for 2018 presented in this report are based on the new standard and show estimates for single-race groups. These estimates are not completely comparable with those of previous years, which are based on bridged-race groups. To show trends and document the impact of changing to the 1997 standards, life expectancy estimates for 2006-2018 are reported for bridged-race categories that were in use starting with data year 2000. Results-In 2018, the overall expectation of life at birth was 78.7 years, increasing from 78.6 in 2017. Between 2017 and 2018, life expectancy at birth increased by 0.1 year for males (76.1 to 76.2) and females (81.1 to 81.2). In 2018, life expectancy at birth was 81.8 for the Hispanic population, 78.6 for the non-Hispanic single-race white population, and 74.7 for the non-Hispanic single-race black population. All material appearing in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.

Entities:  

Year:  2020        PMID: 33270553

Source DB:  PubMed          Journal:  Natl Vital Stat Rep        ISSN: 1551-8922


  36 in total

1.  Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer.

Authors:  Shuxia Qin; Lidan Yi; Sini Li; Chongqing Tan; Xiaohui Zeng; Liting Wang; Ye Peng; Xiaomin Wan
Journal:  Adv Ther       Date:  2021-05-21       Impact factor: 3.845

2.  First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis.

Authors:  Ye Peng; Xiaohui Zeng; Liubao Peng; Qiao Liu; Lidan Yi; Xia Luo; Sini Li; Liting Wang; Shuxia Qin; Xiaomin Wan; Chongqing Tan
Journal:  Adv Ther       Date:  2021-04-05       Impact factor: 3.845

3.  Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer.

Authors:  Ye Peng; Xiaohui Zeng; Liubao Peng; Qiao Liu; Lidan Yi; Xia Luo; Sini Li; Liting Wang; Shuxia Qin; Xiaomin Wan; Chongqing Tan
Journal:  Adv Ther       Date:  2021-06-07       Impact factor: 3.845

4.  Marital and Romantic Satisfaction among Older African Americans.

Authors:  Antonius D Skipper; Robert Joseph Taylor
Journal:  Annu Rev Gerontol Geriatr       Date:  2021

5.  Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States.

Authors:  Ye Peng; Zhihua She; Liubao Peng; Qiao Liu; Lidan Yi; Xia Luo; Sini Li; Liting Wang; Shuxia Qin; Xiaomin Wan; Chongqing Tan
Journal:  Adv Ther       Date:  2021-10-24       Impact factor: 3.845

6.  Trends in Differences in Health Status and Health Care Access and Affordability by Race and Ethnicity in the United States, 1999-2018.

Authors:  Shiwani Mahajan; César Caraballo; Yuan Lu; Javier Valero-Elizondo; Daisy Massey; Amarnath R Annapureddy; Brita Roy; Carley Riley; Karthik Murugiah; Oyere Onuma; Marcella Nunez-Smith; Howard P Forman; Khurram Nasir; Jeph Herrin; Harlan M Krumholz
Journal:  JAMA       Date:  2021-08-17       Impact factor: 56.272

7.  The Effect of the COVID-19 Pandemic on the Elderly: Population Fatality Rates, COVID Mortality Percentage, and Life Expectancy Loss.

Authors:  Paula Natalia Barreto Parra; Vladimir Atanasov; Jeff Whittle; John Meurer; Qian Eric Luo; Ruohao Zhang; Bernard Black
Journal:  Elder Law J       Date:  2022-02-17

8.  Assessing the Optimality of a COVID Lockdown in the United States.

Authors:  Anna Scherbina
Journal:  Econ Disaster Clim Chang       Date:  2021-05-08

9.  Effect of the covid-19 pandemic in 2020 on life expectancy across populations in the USA and other high income countries: simulations of provisional mortality data.

Authors:  Steven H Woolf; Ryan K Masters; Laudan Y Aron
Journal:  BMJ       Date:  2021-06-23

10.  Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

Authors:  SiNi Li; JianHe Li; LiuBao Peng; YaMin Li; XiaoMin Wan
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.